LabCorp Enhances Cancer Testing Capability With $600 Mil. Dianon Purchase
This article was originally published in The Gray Sheet
Executive Summary
LabCorp says it does not foresee antitrust issues with the Federal Trade Commission related to the acquisition of cancer testing firm Dianon
You may also be interested in...
Correlogic Ovarian Cancer Test Market Advance Supported By NCI/FDA, Labs
Quest and LabCorp are vowing to offer a "homebrew" ovarian cancer test based on Correlogic's computer artificial intelligence technology by year-end
Correlogic Ovarian Cancer Test Market Advance Supported By NCI/FDA, Labs
Quest and LabCorp are vowing to offer a "homebrew" ovarian cancer test based on Correlogic's computer artificial intelligence technology by year-end
Quest/Unilab
Quest Diagnostics will submit more information on its proposed acquisition of diagnostic testing services firm Unilab following a request from the Federal Trade Commission. Completion of the $1.1 bil. purchase, first announced April 2, is expected to be delayed until the third quarter (1"The Gray Sheet" April 8, 2002, p. 19)...